Efficacy of ustekinumab, vedolizumab, or a second anti-TNF agent after the failure of a first anti-TNF agent in patients with Crohn’s disease: a multicentre retrospective study - Archive ouverte HAL Accéder directement au contenu
Article Dans Une Revue BMC Gastroenterology Année : 2022

Efficacy of ustekinumab, vedolizumab, or a second anti-TNF agent after the failure of a first anti-TNF agent in patients with Crohn’s disease: a multicentre retrospective study

, (1) , (2) , (3) , (4, 5) , (6) , (7) , (8) , (9, 10) , (11, 12) , (12) , (13, 14) , (15)
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15

Résumé

Abstract Background No study has performed a face-to-face comparison of biologics after the failure of the first anti-TNF agent in patients with Crohn’s disease (CD). The aim of the study was to compare the efficacy of biologics in this setting. Methods Patients with CD who were refractory to a first anti-TNF agent, and treated with ustekinumab (UST), vedolizumab (VDZ), or a second anti-TNF drug as a second-line biological agent at 10 French tertiary centres from 2013 to 2019 were retrospectively included in this study. Results Among the 203 patients included, 90 (44%) received UST, 42 (21%) received VDZ and 71 (35%) received a second anti-TNF agent. The first anti-TNF agent was discontinued due to a primary nonresponse in 42 (21%) patients. At weeks 14–24, the rates of steroid-free remission were similar between the UST, VDZ and second anti-TNF groups (29%, 38% and 44%, respectively, p = 0.15). With a mean follow-up of 118 weeks, drug survival was shorter for patients who received ustekinumab treatment ( p = 0.001). In the case of trough level less than 5 µg/ml, patients treated with a second anti-TNF agent had a higher postinduction remission rate ( p = 0.002), and drug survival ( p = 0.0005). No other relevant factors were associated with treatment efficacy, including trough levels greater than 5 µg/ml. Conclusions VDZ, UST and a second anti-TNF agent exhibit similar efficacy in the short term, as second-biological line treatment in patients with CD who are refractory to a first anti-TNF agent, but shorter drug maintenance is observed for patients treated with UST.
Fichier principal
Vignette du fichier
s12876-022-02583-5 (1.57 Mo) Télécharger le fichier
Origine : Fichiers éditeurs autorisés sur une archive ouverte

Dates et versions

hal-03890189 , version 1 (23-01-2023)

Identifiants

Citer

Rayer Cassandra, Maria Nachury, Bourreille Arnaud, Roblin Xavier, Peyrin-Biroulet Laurent, et al.. Efficacy of ustekinumab, vedolizumab, or a second anti-TNF agent after the failure of a first anti-TNF agent in patients with Crohn’s disease: a multicentre retrospective study. BMC Gastroenterology, 2022, 22 (1), pp.498. ⟨10.1186/s12876-022-02583-5⟩. ⟨hal-03890189⟩
0 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Facebook Twitter LinkedIn More